161 related articles for article (PubMed ID: 20031032)
21. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study.
König TE; van der Houwen LE; Overbeek A; Hendriks ML; Beutler-Beemsterboer SN; Kuchenbecker WK; Renckens CN; Bernardus RE; Schats R; Homburg R; Hompes PG; Lambalk CB
Hum Reprod; 2013 Oct; 28(10):2804-12. PubMed ID: 23838159
[TBL] [Abstract][Full Text] [Related]
22. A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count.
Jayaprakasan K; Hopkisson J; Campbell B; Johnson I; Thornton J; Raine-Fenning N
BJOG; 2010 Jun; 117(7):853-62. PubMed ID: 20353458
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Pergoveris in Assisted Reproductive Technology--ESPART: rationale and design of a randomised controlled trial in poor ovarian responders undergoing IVF/ICSI treatment.
Humaidan P; Schertz J; Fischer R
BMJ Open; 2015 Jul; 5(7):e008297. PubMed ID: 26141305
[TBL] [Abstract][Full Text] [Related]
24. Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles.
Mochtar MH; Danhof NA; Ayeleke RO; Van der Veen F; van Wely M
Cochrane Database Syst Rev; 2017 May; 5(5):CD005070. PubMed ID: 28537052
[TBL] [Abstract][Full Text] [Related]
25. Effects of recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-agonist protocol: a matched case-control study.
Franco JG; Baruffi RL; Oliveira JB; Mauri AL; Petersen CG; Contart P; Felipe V
Reprod Biol Endocrinol; 2009 Jun; 7():58. PubMed ID: 19497101
[TBL] [Abstract][Full Text] [Related]
26. Effects of recombinant LH treatment on folliculogenesis and responsiveness to FSH stimulation.
Durnerin CI; Erb K; Fleming R; Hillier H; Hillier SG; Howles CM; Hugues JN; Lass A; Lyall H; Rasmussen P; Thong J; Traynor I; Westergaard L; Yates R;
Hum Reprod; 2008 Feb; 23(2):421-6. PubMed ID: 18084048
[TBL] [Abstract][Full Text] [Related]
27. Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy.
Kolibianakis EM; Albano C; Kahn J; Camus M; Tournaye H; Van Steirteghem AC; Devroey P
Fertil Steril; 2003 Apr; 79(4):873-80. PubMed ID: 12749423
[TBL] [Abstract][Full Text] [Related]
28. A direct healthcare cost analysis of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol.
Chang JC; Yi YC; Chen YF; Guu HF; Kung HF; Chen LY; Chuan ST; Chang YM; Chen MJ
Arch Gynecol Obstet; 2024 Feb; 309(2):699-706. PubMed ID: 38099955
[TBL] [Abstract][Full Text] [Related]
29. Flexibility in starting ovarian stimulation at different phases of the menstrual cycle for treatment of infertile women with the use of in vitro fertilization or intracytoplasmic sperm injection.
Qin N; Chen Q; Hong Q; Cai R; Gao H; Wang Y; Sun L; Zhang S; Guo H; Fu Y; Ai A; Tian H; Lyu Q; Daya S; Kuang Y
Fertil Steril; 2016 Aug; 106(2):334-341.e1. PubMed ID: 27114329
[TBL] [Abstract][Full Text] [Related]
30. Bioequivalence of recombinant human FSH and recombinant human LH in a fixed 2:1 combination: two phase I, randomised, crossover studies.
Picard M; Rossier C; Papasouliotis O; Lugan I
Curr Med Res Opin; 2008 Apr; 24(4):1199-208. PubMed ID: 18348746
[TBL] [Abstract][Full Text] [Related]
31. Suppression of LH during ovarian stimulation: analysing threshold values and effects on ovarian response and the outcome of assisted reproduction in down-regulated women stimulated with recombinant FSH.
Balasch J; Vidal E; Peñarrubia J; Casamitjana R; Carmona F; Creus M; Fábregues F; Vanrell JA
Hum Reprod; 2001 Aug; 16(8):1636-43. PubMed ID: 11473955
[TBL] [Abstract][Full Text] [Related]
32. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization.
Devroey P; Fauser BC; Platteau P; Beckers NG; Dhont M; Mannaerts BM
J Clin Endocrinol Metab; 2004 May; 89(5):2062-70. PubMed ID: 15126522
[TBL] [Abstract][Full Text] [Related]
33. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
34. Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): a role for LH in the final stages of follicular maturation.
Sullivan MW; Stewart-Akers A; Krasnow JS; Berga SL; Zeleznik AJ
J Clin Endocrinol Metab; 1999 Jan; 84(1):228-32. PubMed ID: 9920089
[TBL] [Abstract][Full Text] [Related]
35. Follicular development induced by recombinant luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in anovulatory women with LH and FSH deficiency: evidence of a threshold effect.
O'Dea L; O'Brien F; Currie K; Hemsey G
Curr Med Res Opin; 2008 Oct; 24(10):2785-93. PubMed ID: 18727841
[TBL] [Abstract][Full Text] [Related]
36. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos?
Drakopoulos P; Blockeel C; Stoop D; Camus M; de Vos M; Tournaye H; Polyzos NP
Hum Reprod; 2016 Feb; 31(2):370-6. PubMed ID: 26724797
[TBL] [Abstract][Full Text] [Related]
37. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles.
Yu S; Long H; Chang HY; Liu Y; Gao H; Zhu J; Quan X; Lyu Q; Kuang Y; Ai A
Hum Reprod; 2018 Feb; 33(2):229-237. PubMed ID: 29300975
[TBL] [Abstract][Full Text] [Related]
38. Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm injection patients.
Elgindy EA; El-Haieg DO; El-Sebaey A
Fertil Steril; 2008 Jun; 89(6):1670-6. PubMed ID: 17658520
[TBL] [Abstract][Full Text] [Related]
39. Transdermal testosterone pretreatment in poor responders undergoing ICSI: a randomized clinical trial.
Bosdou JK; Venetis CA; Dafopoulos K; Zepiridis L; Chatzimeletiou K; Anifandis G; Mitsoli A; Makedos A; Messinis IE; Tarlatzis BC; Kolibianakis EM
Hum Reprod; 2016 May; 31(5):977-85. PubMed ID: 26956551
[TBL] [Abstract][Full Text] [Related]
40. Recombinant human luteinizing hormone to trigger ovulation: randomized, controlled, dose-finding pilot study in ovulation induction.
Pierson RA; Olatunbosun OA; Chizen DR; Saunders H; Loumaye E; De Moustier B
J Reprod Med; 2014; 59(7-8):355-66. PubMed ID: 25098025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
